Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 61,034 shares traded hands during trading, an increase of 725% from the previous session’s volume of 7,400 shares.The stock last traded at $10.90 and had previously closed at $11.2550.
Oxford BioMedica Stock Performance
The company has a debt-to-equity ratio of 3.08, a current ratio of 1.89 and a quick ratio of 1.67. The company’s 50 day simple moving average is $10.33 and its two-hundred day simple moving average is $8.68.
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Featured Articles
- Five stocks we like better than Oxford BioMedica
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
